Fingerprint
Dive into the research topics of 'A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically